Latest research on Duloxetine

Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.

Latest findings

Published guidelines for the initial treatment of NP include the use of Gabapentin, Pregabalin, carbamazepine, tricyclic antidepressants, Oxycodone, Morphine, methadone, Tramadol, Duloxetine, and Venlafaxine [10, 11]. [source, 2015]
Duloxetine hydrochloride is a potent and relatively balanced inhibitor of a potent and relatively balanced serotonin-norepinephrine reuptake inhibitor (SNRI). [source, 2016]
The findings from clinical trials have shown that treatment with Duloxetine improves clinical outcomes in patients with MDD. [source, 2016]
In particular, in line with its pain-related indications, the effects of Duloxetine, compared to other classes of antidepressants, have been found to be more apparent in a subgroup of MDD patients with PPS. [source, 2016]
The present post hoc analysis examined the course of impaired functioning during the treatment of patients with MDD and compared the level of functioning in patients treated with Duloxetine or a selective serotonin reuptake inhibitor (SSRI) for up to 6 months in a naturalistic setting in East Asia, using data from a 6-month prospective observational study. [source, 2016]
In Japan, the daily dose of Duloxetine is limited to a maximum of 60 mg/day for the treatment of MDD. [source, 2016]
Although our study did not include Japan, we also limited the maximum dose of Duloxetine to 60 mg/day to ensure that our results have broader implications across East Asia including Japan. [source, 2016]
The present analysis included only those patients who initiated either Duloxetine with a daily dose of ≤60 mg (Duloxetine cohort) or an SSRI (SSRI cohort) at approved therapeutic dosages, both as monotherapy at baseline. [source, 2016]
This study included a total of 452 patients who 1) initiated either Duloxetine with a daily dose of ≤60 mg or an SSRI as monotherapy at baseline for the treatment of MDD and 2) who did not have missing data on the QIDS-SR16 score at baseline with at least one nonmissing QIDS-SR16 score during follow-up (n=227 in the Duloxetine group and n=225 in the SSRI group). [source, 2016]
It also analyzed the patient observations up to the point where their initial medications were discontinued (n=176 [77.5%] in the Duloxetine group and n=167 [74.2%] in the SSRI group available at 24 weeks). [source, 2016]